Abstract:

INTRODUCTION: Pancreatic adenocarcinoma is one of the deadliest cancers. Effective, simple and practical methods that can be used in daily life are still lacking to predict the prognosis of patients with advanced pancreatic cancer and a promising biomarker is needed to predict prognosis. Our study's objective was to demonstrate the correlation between the HALP score and prognosis in patients with metastatic pancreatic cancer. METHODS: Patients diagnosed with metastatic pancreatic cancer from 4 centers in Turkey between 2016 and 2022 were included. Demographic data, hemogram parameters, biochemistry values, as well as the treatments received were recorded. Survivals were also recorded RESULTS: There were 280 patients in our study. The median PFS was 7.53 months, while the median OS was 11.53 months for the whole population. Median PFS was 7.1 months for the HALP-Low group and 14.8 months for the HALP-High group. The HALP-Low group exhibited a significantly shorter median progression-free survival (PFS) compared to the HALP-High group, with a statistically significant difference between the two groups (p<0.001). Median OS was 10.57 months for the HALP-Low group and 18 months for the HALP-High group. The HALP-Low group demonstrated a significantly shorter median overall survival (OS) compared to the HALP-High group, with a statistically significant difference between the two groups (p<0.001) DISCUSSION AND CONCLUSION: In conclusion, the HALP score is an inexpensive, practical, literature-contributing marker and, if validated by prospective studies, can be used in routine clinical practice to predict the prognosis of patients with metastatic pancreatic cancer.

Keywords: